A case series and systematic literature review of anakinra and immunosuppression in idiopathic recurrent pericarditis

Scott, Ian C.; Hajela, Vijay; Hawkins, Philip N.; Lachmann, HJ

doi:10.1016/j.jccase.2011.07.003

Cited by 31 publications

(25 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, not all patients respond to this regimen and some go on to have recurrent bouts of inflammation. Anakinra treatment provides a prompt cessation of symptoms 70 .…”

Section: Il-1-mediated Inflammatory Conditionsmentioning

confidence: 99%

“…For example, treating idiopathic recurrent pericarditis with immunosuppressive agents, anti- TNF antibodies, NSAIDs, intravenous gamma globulin or high-dose glucocorticoids often results in partial remissions, whereas anakinra or canakinumab provide complete remission in all reported cases 70,157–159 . Although most chronic inflammatory conditions without a known basis can be controlled with glucocorticoids, monotherapy with IL-1 blockade can provide improved control without the metabolic and gastrointestinal side effects.…”

Section: Clinical Trials Of Il-1-targeting Agentsmentioning

confidence: 99%

See 1 more Smart Citation

Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases

Dinarello

Simon²,

Meer³

2012

Nat Rev Drug Discov

1,558

1,305

View full text Add to dashboard Cite

Interleukin-1 (IL-1) is a highly active pro-inflammatory cytokine that lowers pain thresholds and damages tissues. Monotherapy blocking IL-1 activity in autoinflammatory syndromes results in a rapid and sustained reduction in disease severity, including reversal of inflammation-mediated loss of sight, hearing and organ function. This approach can therefore be effective in treating common conditions such as post-infarction heart failure, and trials targeting a broad spectrum of new indications are underway. So far, three IL-1-targeted agents have been approved: the IL-1 receptor antagonist anakinra, the soluble decoy receptor rilonacept and the neutralizing monoclonal anti-IL-1β antibody canakinumab. In addition, a monoclonal antibody directed against the IL-1 receptor and a neutralizing anti-IL-1α antibody are in clinical trials.

show abstract

“…However, not all patients respond to this regimen and some go on to have recurrent bouts of inflammation. Anakinra treatment provides a prompt cessation of symptoms 70 .…”

Section: Il-1-mediated Inflammatory Conditionsmentioning

confidence: 99%

Section: Clinical Trials Of Il-1-targeting Agentsmentioning

confidence: 99%

Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases

Dinarello

Simon²,

Meer³

2012

Nat Rev Drug Discov

1,558

1,305

View full text Add to dashboard Cite

show abstract

“…Although patients with AOSD and also other autoinflammatory diseases will have manifestation of pericarditis that is resolved with anakinra, canakinumab or rilonacept, idiopathic recurrent pericarditis is also responsive to anakinra [121–123,164–167]. …”

Section: Other Indications For Treating Il-1-mediated Inflammationmentioning

confidence: 99%

Treating inflammation by blocking interleukin-1 in humans

Dinarello¹,

Meer²

2013

Seminars in Immunology

491

349

View full text Add to dashboard Cite

IL-1 is a master cytokine of local and systemic inflammation. With the availability of specific IL-1 targeting therapies, a broadening list of diseases has revealed the pathologic role of IL-1-mediated inflammation. Although IL-1, either IL-1α or IL-1β, was administered to patients in order to improve bone marrow function or increase host immune responses to cancer, these patients experienced unacceptable toxicity with fever, anorexia, myalgias, arthralgias, fatigue, gastrointestinal upset and sleep disturbances; frank hypotension occurred. Thus it was not unexpected that specific pharmacological blockade of IL-1 activity in inflammatory diseases would be beneficial. Monotherapy blocking IL-1 activity in a broad spectrum of inflammatory syndromes results in a rapid and sustained reduction in disease severity. In common conditions such as heart failure and gout arthritis, IL-1 blockade can be effective therapy. Three IL-1blockers have been approved: the IL-1 receptor antagonist, anakinra, blocks the IL-1 receptor and therefore reduces the activity of IL-1α and IL-1β. A soluble decoy receptor, rilonacept, and a neutralizing monoclonal anti-interleukin-1β antibody, canakinumab, are also approved. A monoclonal antibody directed against the IL-1 receptor and a neutralizing anti-IL-1α are in clinical trials. By specifically blocking IL-1, we have learned a great deal about the role of this cytokine in inflammation but equally important, reducing IL-1 activity has lifted the burden of disease for many patients.

show abstract

“…[11][12][13][14][15][16][17][18][19][20][21][22] Anakinra is a recombinant form of the naturally occurring interleukin-1 (IL-1) receptor antagonist. 23 It is a biologic response modifier that acts by antagonizing the biologic effects of IL-1, which is a proinflammatory cytokine.…”

Section: Introductionmentioning

confidence: 99%

“…25 However, the experience on its use in cases of refractory idiopathic recurrent pericarditis consists of a limited number of case series and case reports. [11][12][13][14][15][16][17][18][19][20][21] In this review, we aimed to summarize the available data concerning the safety and efficacy of anakinra in patients with refractory idiopathic recurrent pericarditis.…”

Section: Introductionmentioning

confidence: 99%